Allevi, formerly BioBots, has undergone a few changes this year from a new CEO to a new home in Philadelphia as it seeks to make its 3D bioprinter technology more competitive.
The high costs of clinical trials could eventually make 3-D bioprinting a go-to technology for pharma and biotech, providing better data to spot toxicity early and helping the pharma industry avoid costly mistakes.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
BioBots, a Philadelphia startup that develops 3D bioprinters, will debut its new $10,000, desktop machine that will help scientists print out their own tissues for preclinical research.
Biobots, Freenome, LignaMed, Telesis and OriMAbs - all life sciences startups - have taken residence in Philadelphia's University Science Center accelerator. Their focuses range from cancer diagnostics to 3D bioprinting.
A company that’s developed its own 3D bioprinter for engineers and researchers interested in advancing 3D printing applications for biologics launched the device at DreamIt Health’s demo day this week. Most people are familiar with 3D printing applications in healthcare from the publicity generated from orthopedic products such as bone implants made from plastic. But […]
That was my question when I spoke with DreamIt Health newbie BioBots, specifically co-founder Ricardo Solorzano. He has spent three years working on technology to develop low-cost 3D bioprinters that research scientists can use to develop biomaterials. The company was formed by a couple of University of Pennsylvania graduates. They view it as a way […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.